SG11201506494XA - Methods for purifying antibodies - Google Patents

Methods for purifying antibodies

Info

Publication number
SG11201506494XA
SG11201506494XA SG11201506494XA SG11201506494XA SG11201506494XA SG 11201506494X A SG11201506494X A SG 11201506494XA SG 11201506494X A SG11201506494X A SG 11201506494XA SG 11201506494X A SG11201506494X A SG 11201506494XA SG 11201506494X A SG11201506494X A SG 11201506494XA
Authority
SG
Singapore
Prior art keywords
methods
purifying antibodies
antibodies
purifying
Prior art date
Application number
SG11201506494XA
Other languages
English (en)
Inventor
Kent E Goklen
Eric J Suda
Antonio Raul Ubiera
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50391244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201506494X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of SG11201506494XA publication Critical patent/SG11201506494XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/22Affinity chromatography or related techniques based upon selective absorption processes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804Affinity chromatography
    • B01D15/3809Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065Purification, fragmentation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
SG11201506494XA 2013-03-15 2014-03-13 Methods for purifying antibodies SG11201506494XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361787309P 2013-03-15 2013-03-15
PCT/IB2014/059755 WO2014141150A1 (en) 2013-03-15 2014-03-13 Methods for purifying antibodies

Publications (1)

Publication Number Publication Date
SG11201506494XA true SG11201506494XA (en) 2015-09-29

Family

ID=50391244

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201506494XA SG11201506494XA (en) 2013-03-15 2014-03-13 Methods for purifying antibodies

Country Status (15)

Country Link
US (2) US10676503B2 (ja)
EP (3) EP3680000B1 (ja)
JP (2) JP6599773B2 (ja)
KR (1) KR102114021B1 (ja)
CN (1) CN105188872B (ja)
AU (1) AU2014229280B2 (ja)
BR (1) BR112015022321A2 (ja)
CA (1) CA2902287A1 (ja)
DK (2) DK2969098T3 (ja)
ES (1) ES2765206T3 (ja)
IL (1) IL240753B (ja)
RU (1) RU2651483C2 (ja)
SG (1) SG11201506494XA (ja)
TW (1) TWI625335B (ja)
WO (1) WO2014141150A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI625335B (zh) * 2013-03-15 2018-06-01 Glaxosmithkline Intellectual Property (No. 2) Limited 純化抗體的方法
WO2014186350A1 (en) 2013-05-15 2014-11-20 Medimmune Limited Purification of recombinantly produced polypeptides
JP6700197B2 (ja) 2014-04-30 2020-05-27 ノヴォ ノルディスク アー/エス カプリル酸を用いてタンパク質を精製する方法
WO2016121701A1 (ja) 2015-01-26 2016-08-04 株式会社カネカ 免疫グロブリンκ鎖可変領域含有タンパク質精製用アフィニティー分離マトリックス
JP6663360B2 (ja) 2015-01-26 2020-03-11 株式会社カネカ 変異型免疫グロブリンκ鎖可変領域結合性ペプチド
WO2017195638A1 (ja) * 2016-05-09 2017-11-16 株式会社カネカ 抗体またはκ鎖可変領域含有抗体断片の精製方法
CA3035853A1 (en) 2016-09-07 2018-03-15 Glaxosmithkline Intellectual Property Development Limited Methods for purifying antibodies
CN106939045B (zh) * 2017-05-01 2020-03-31 深圳市国创纳米抗体技术有限公司 一种单克隆抗体细胞培养液澄清的方法
CN108085358A (zh) * 2018-02-08 2018-05-29 保定冀中药业有限公司 一种犬细小病毒单克隆抗体IgG2b-Fab片段的制备方法
TW202003555A (zh) 2018-03-07 2020-01-16 英商葛蘭素史克智慧財產發展有限公司 用於純化重組多肽之方法
TW202000891A (zh) * 2018-03-07 2020-01-01 英商葛蘭素史克智慧財產發展有限公司 純化抗體之方法
CN114133446A (zh) * 2021-12-31 2022-03-04 方坦思(上海)生物医药有限公司 单克隆抗体的纯化方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US6955917B2 (en) 1997-06-20 2005-10-18 Bayer Healthcare Llc Chromatographic method for high yield purification and viral inactivation of antibodies
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
EP1584242B1 (en) * 2001-06-01 2010-01-20 Upfront Chromatography A/S Fractionation of protein containing mixtures
EP1419179B1 (en) 2001-08-10 2010-03-03 Aberdeen University Antigen binding domains from fish
CN100403028C (zh) 2002-05-31 2008-07-16 印度农业研究委员会 Bt-cry毒素的迅速检测
BRPI0508096B8 (pt) * 2004-02-27 2021-05-25 Octapharma Ag método de preparação de um preparado de anticorpo seguro purificado contra vírus e vírus inativado
EP1786827A4 (en) * 2004-05-14 2008-10-29 Kirin Holdings Kk PROCESS FOR IMMUNOGLOBULINE CLEANING
US8263750B2 (en) 2006-03-16 2012-09-11 Amgen Inc. Method for purifying a protein using protein-A affinity chromatography using an intermediate wash step
US20080167450A1 (en) * 2007-01-05 2008-07-10 Hai Pan Methods of purifying proteins
CN107915769A (zh) 2011-03-29 2018-04-17 葛兰素史密斯克莱有限责任公司 用于蛋白纯化的缓冲液体系
TWI625335B (zh) 2013-03-15 2018-06-01 Glaxosmithkline Intellectual Property (No. 2) Limited 純化抗體的方法
WO2014186350A1 (en) 2013-05-15 2014-11-20 Medimmune Limited Purification of recombinantly produced polypeptides

Also Published As

Publication number Publication date
KR20150131235A (ko) 2015-11-24
US20200277330A1 (en) 2020-09-03
RU2651483C2 (ru) 2018-04-19
EP3680000B1 (en) 2024-03-13
EP3680000A1 (en) 2020-07-15
TWI625335B (zh) 2018-06-01
AU2014229280A1 (en) 2015-10-01
IL240753A0 (en) 2015-10-29
ES2765206T3 (es) 2020-06-08
BR112015022321A2 (pt) 2017-07-18
DK2969098T3 (da) 2020-01-27
JP2016519052A (ja) 2016-06-30
AU2014229280B2 (en) 2017-01-05
EP4371996A2 (en) 2024-05-22
TW201522365A (zh) 2015-06-16
CN105188872B (zh) 2019-01-15
CA2902287A1 (en) 2014-09-18
JP7002511B2 (ja) 2022-02-21
US10676503B2 (en) 2020-06-09
DK3680000T3 (da) 2024-04-02
KR102114021B1 (ko) 2020-05-22
JP2020019795A (ja) 2020-02-06
EP2969098A1 (en) 2016-01-20
EP2969098B1 (en) 2019-10-30
CN105188872A (zh) 2015-12-23
IL240753B (en) 2021-01-31
US20160024146A1 (en) 2016-01-28
RU2015136860A (ru) 2017-04-28
JP6599773B2 (ja) 2019-10-30
WO2014141150A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
IL269528A (en) Anti- FCRH5 antibodies
HK1217344A1 (zh) 單克隆抗體的純化工序
PT3004163T (pt) Método para purificação de anticorpo
GB201322583D0 (en) Antibodies
IL240753A0 (en) Antibody purification methods
HK1220142A1 (zh) 抗體
GB201308658D0 (en) Antibodies
EP2987801A4 (en) PROCESS FOR PURIFYING ANTIBODY PROTEIN
GB201315486D0 (en) Antibodies
IL245488B (en) Anti- ccl17 antibodies
GB201318283D0 (en) Antibodies